We evaluated an all-oral regimen comprising the nucleotide polymerase inhibitor sofosbuvir ( SOF ) with the NS@A inhibitor ledipasvir ( LDV ) or the NS@B non-nucleoside inhibitor GS-@ in patients with genotype @ hepatitis C virus ( HCV ) infection .